DPP: niche domestic pharma with reasonable multiples but execution and liquidity constraints
Intrinsic value VND 29,643 vs market VND 26,500 — implied upside 11.9% (model confidence: low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược Đồng Nai (DPP) is a UPCom-listed domestic pharmaceutical manufacturer and distributor operating in the Vietnamese Dược phẩm segment. The company reported revenues of VND 419.1 bn in 2025 after a peak of VND 441.5 bn in 2024 and has a concentrated shareholder base with two institutions owning a combined 65.0% (largest: Công ty Cổ phần Chế biến Xuất nhập khẩu Nông sản Thực phẩm Đồng Nai at 51.5%). DPP's business is capital- and distribution-intensive; its balance sheet shows total assets of VND 132.5 bn in 2025 and the company pays a meaningful cash yield (dividend yield 5.7%).
Luận điểm đầu tư
DPP's valuation and operating metrics point to a value-oriented profile but with execution and liquidity caveats. At current price VND 26,500, the blended intrinsic value is VND 29,643 (11.9% upside) derived from a 70/30 blend of a DCF (VND 43,272.6) and PE approach (VND 31,853.1); the model uses WACC 10% and terminal growth 4%. Operationally, DPP delivers attractive capital returns for the sector: ROE 18.5% and ROA 8.7% (latest), supported by improving net profit (VND 10.9 bn in 2025 vs VND 8.3 bn in 2023) and strong revenue growth in 2024 (Revenue YoY +36.5%).
However, several offsetting factors limit conviction. Trading liquidity is effectively nil (avg_volume_2w = 0.0) and foreign ownership room is 0.0%, constraining market access and institutional re-rating catalysts. The model's confidence is explicitly low; calibration flagged the stock as illiquid. Earnings quality is moderate at 62.7/100, which together with a null M-Score and no forensic flags suggests no obvious accounting manipulation but still leaves room for ordinary reporting noise under VAS. Debt metrics show Debt/Equity 1.146, implying leverage risk versus peers if the business faces demand softness.
The combination of single-digit P/E (7.3x) and low EV/EBITDA (4.3x) versus sector peers supports upside potential, but the limited liquidity, concentrated ownership (51.5% largest holder), and low model confidence mean the implied 11.9% upside is insufficient to compensate for execution and marketability risk.
Diễn giải định giá
Blended intrinsic valuation: 70% DCF, 30% PE; DCF uses WACC 10% and terminal growth 4% with a 10-year explicit projection.
- DCF intrinsic component: VND 43,272.6 per share (70% weight).
- PE intrinsic component: VND 31,853.1 per share (30% weight) using a fair PE of 8.73.
- WACC 10% and terminal g 4% drive a high TV share (model TV_pct 57.07%).
- Base free cash flow input: VND 7,218,846,915 (model base_fcf) and reinvestment/reinvestment_rate 14.03%.
- Net leverage and effective cash balance implied in model (negative reported net debt in inputs) reduce enterprise value.
The blended intrinsic of VND 29,643 implies limited upside (11.9%) from today's VND 26,500. Model confidence is low, driven by illiquidity and calibration steps (isotonic); therefore the intrinsic should be treated as directional rather than precise. Key sensitivities are WACC, terminal growth and the fair PE assumption; execution or a re-rating would be required to exceed the model upside materially.
Các luận điểm cần cân nhắc
- Attractive trailing multiples: P/E 7.3x and EV/EBITDA 4.3x provide re-rating potential if earnings scale.
- ROE 18.5% indicates efficient use of equity compared with many local peers.
- Revenue recovered after 2024 (VND 441.5 bn) and remained sizable at VND 419.1 bn in 2025; net profit improved to VND 10.9 bn in 2025.
- Dividend yield 5.7% offers cash return while waiting for rerating.
- Marketability risk: average 2-week trading volume is effectively zero and model sanity flagged 'illiquid', constraining exit options for large buyers.
- Concentrated ownership (largest holder 51.5%) limits free float and potential for substantial foreign ownership (foreign_room 0.0%).
- Model confidence is low; blended intrinsic relies heavily on DCF assumptions (WACC 10%, terminal g 4%) and TV accounts for ~57.1% of value, increasing sensitivity to small input changes.
- Leverage is meaningful (Debt/Equity 1.15) increasing vulnerability to margin pressure; net profit margin is only 2.6%, leaving limited buffer for cost shocks.
Bối cảnh ngành
The Vietnamese pharmaceutical segment operates under VAS accounting and a mix of domestic and multinational competition. Local manufacturers like DPP compete on distribution reach and product registration; regulatory timelines for drug approvals and government procurement policies can materially affect sales. SBV macro measures and credit growth quotas can limit working-capital financing for mid-sized producers. Compared with 351 peers, the sector median upside is ~12.1% — DPP's 11.9% implied upside is near the median but its low confidence and illiquidity differentiate it from higher-conviction names. SOE-related or institutional majority shareholdings are common in the segment and tend to depress free float; foreign ownership limits (foreign_room 0.0%) prevent FDI-driven rerating. Finally, peer comparables show some high-confidence rerating opportunities (top peer upside examples >36%), but those peers typically have better liquidity or higher model confidence.
Yếu tố rủi ro
- Liquidity risk: avg_volume_2w = 0.0, making large trades difficult and increasing bid-ask impact.
- Shareholder concentration: largest holder 51.5% reduces free float and potential for active corporate governance or market repricing.
- Model and valuation risk: intrinsic upside 11.9% with 'low' model confidence — sensitive to WACC, terminal g and fair PE inputs.
- Operational margin pressure: net profit margin 2.6% and EBIT margin 3.5% offer limited cushion against raw material or distribution cost increases.
- Funding/leverage risk: Debt/Equity 1.15 exposes the company to higher interest costs and refinancing risk if operating cash generation weakens.
- Regulatory and procurement risk: changes in state procurement, pricing controls, or drug registration delays can materially affect top-line growth under VAS.
- Foreign ownership and market-access risk: foreign_room 0.0% prevents incremental foreign strategic investment as a rerating catalyst.
Yếu tố có thể tác động
- Improved liquidity or listing migration that increases average trading volume and foreign room.
- A step-up in margins or a clear product-line scale that increases EPS above the current trend (EPS VND 3,650).
- Corporate actions that reduce shareholder concentration or unlock free float (e.g., sell-down by largest institutional holder).
- Positive regulatory outcomes (faster registrations, inclusion in public procurement lists) that lift revenue beyond current modeling assumptions.
Đánh giá dấu hiệu kế toán
There is no M-Score provided and no explicit forensic red flags in the input. Earnings quality is moderate at 62.7/100, suggesting results are neither clearly pristine nor alarmingly opaque. Given VAS accounting and the lack of a formal M-Score, the primary forensic concern is ordinary reporting noise rather than manipulation; continued monitoring of cash flow conversion and related-party transactions is warranted.
Lịch sử định giá
The model's historical track record spans 12 years with a hit rate of 72.7% (years where directional calls matched next-year price direction) and an average realized upside of 219.2% in successful years. While the hit rate is respectable, the outsized average upside is skewed by a subset of large winners; therefore past performance should be interpreted cautiously and not extrapolated as a guarantee of future outcomes.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-11 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.